genOway Société anonyme Past Earnings Performance
Past criteria checks 5/6
genOway Société anonyme has been growing earnings at an average annual rate of 57.9%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 10% per year. genOway Société anonyme's return on equity is 9.2%, and it has net margins of 7.8%.
Key information
57.9%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | 10.0% |
| Return on equity | 9.2% |
| Net Margin | 7.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
genOway Société anonyme's (EPA:ALGEN) Price Is Right But Growth Is Lacking
Jan 20
We Think genOway Société anonyme (EPA:ALGEN) Can Stay On Top Of Its Debt
Sep 27We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
May 31We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
Nov 01Revenue & Expenses BreakdownBeta
How genOway Société anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 20 | 2 | 0 | 0 |
| 30 Sep 23 | 21 | 2 | 4 | 0 |
| 30 Jun 23 | 23 | 2 | 9 | 0 |
| 31 Mar 23 | 22 | 1 | 8 | 0 |
| 31 Dec 22 | 21 | 1 | 8 | 0 |
| 30 Sep 22 | 20 | 1 | 6 | 0 |
| 30 Jun 22 | 21 | 1 | 8 | 0 |
| 31 Mar 22 | 20 | 0 | 8 | 0 |
| 31 Dec 21 | 20 | 0 | 8 | 0 |
| 30 Sep 21 | 20 | 0 | 10 | 0 |
| 30 Jun 21 | 18 | 0 | 8 | 0 |
| 31 Mar 21 | 17 | -1 | 8 | 0 |
| 31 Dec 20 | 16 | -1 | 7 | 0 |
| 30 Sep 20 | 16 | -1 | 7 | 0 |
| 30 Jun 20 | 15 | -1 | 7 | 0 |
| 31 Mar 20 | 14 | -1 | 7 | 0 |
| 31 Dec 19 | 14 | -1 | 7 | 0 |
| 30 Sep 19 | 14 | -1 | 7 | 0 |
| 30 Jun 19 | 15 | -1 | 7 | 0 |
| 31 Mar 19 | 15 | 0 | 7 | 0 |
| 31 Dec 18 | 15 | 1 | 6 | 0 |
| 30 Sep 18 | 14 | 1 | 6 | 0 |
| 30 Jun 18 | 13 | 1 | 5 | 0 |
| 31 Mar 18 | 13 | 1 | 5 | 0 |
| 31 Dec 17 | 13 | 2 | 5 | 0 |
| 30 Sep 17 | 13 | 2 | 5 | 0 |
| 30 Jun 17 | 13 | 2 | 5 | 0 |
| 31 Mar 17 | 12 | 1 | 5 | 0 |
| 31 Dec 16 | 12 | 1 | 5 | 0 |
| 30 Sep 16 | 11 | 0 | 5 | 0 |
| 30 Jun 16 | 10 | 0 | 4 | 0 |
| 31 Mar 16 | 10 | 0 | 4 | 0 |
| 31 Dec 15 | 10 | 0 | 4 | 0 |
| 30 Sep 15 | 10 | 0 | 4 | 0 |
| 30 Jun 15 | 10 | 0 | 4 | 0 |
| 31 Mar 15 | 10 | 0 | 4 | 0 |
| 31 Dec 14 | 10 | 0 | 4 | 0 |
| 30 Sep 14 | 10 | 0 | 4 | 0 |
| 30 Jun 14 | 10 | 0 | 4 | 0 |
| 31 Mar 14 | 10 | 0 | 4 | 0 |
| 31 Dec 13 | 10 | 0 | 4 | 0 |
| 30 Sep 13 | 10 | 0 | 4 | 0 |
| 30 Jun 13 | 9 | 0 | 4 | 0 |
Quality Earnings: ALGEN has high quality earnings.
Growing Profit Margin: ALGEN's current net profit margins (7.8%) are higher than last year (3.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALGEN's earnings have grown significantly by 57.9% per year over the past 5 years.
Accelerating Growth: ALGEN's earnings growth over the past year (101.6%) exceeds its 5-year average (57.9% per year).
Earnings vs Industry: ALGEN earnings growth over the past year (101.6%) exceeded the Biotechs industry -11.5%.
Return on Equity
High ROE: ALGEN's Return on Equity (9.2%) is considered low.